Symbicort 160/4.5 mcg 120 doses

Tradename:

Symbicort 160

Symbicort 160

Compound:

budesonide micronized 160 mcg formoterol fumarate dihydrate 4.5 mcg

Auxiliary components:

lactose monohydrate – 730 mcg.

Properties:

Symbicort® contains budesonide and formoterol, which have different mechanisms of action and show an additive effect in reducing the frequency of asthma exacerbations. The special properties of budesonide and formoterol make it possible to use their combination for relief of attacks/symptoms with anti-inflammatory action, or as maintenance therapy for bronchial asthma.

Indications:

bronchial asthma, to achieve general disease control, including prevention and relief of symptoms, and reduce the risk of exacerbations also for the treatment of bronchial asthma of any severity, if the use of inhaled corticosteroids is appropriate; COPD, as symptomatic therapy in patients with post-bronchodilatory FEV1 <70% predicted and with a history of exacerbations despite regular bronchodilator therapy.

Mode of application:

The selection of the dose of the drugs that make up the drug Symbicort® is carried out individually and depending on the severity of the disease. This must be taken into account not only when starting treatment with combined drugs, but also when changing the maintenance dose of the drug.

Patients should be under constant medical supervision for adequate dose selection of Symbicort® Turbuhaler®.

Recommended dose:

Adults over 18 years old: 1-2 inhalations 2 times a day, maximum 4 times a day

Patients 12-17 years old: 1-2 inhalations 2 times a day

Children over 6 years of age (symbicort is indicated for use at a dosage of 80 mcg) 2 inhalations 2 r / day

Symbicort is not recommended for children under 6 years of age.

Contraindications:

– hypersensitivity to budesonide, formoterol or inhaled lactose;

– children under 6 years of age; lactose intolerance, lactase deficiency or glucose-galactose malabsorption).

With caution: pulmonary tuberculosis (active or inactive forms), fungal, viral or bacterial infections of the respiratory system.

Precautionary measures:

During therapy with Symbicort® Turbuhaler®, exacerbations and the development of serious adverse events associated with bronchial asthma may occur. Patients should continue treatment, but seek medical attention if asthma symptoms are not controlled or if the condition worsens after starting therapy.

Side effects:

From the nervous system: often headache; anxiety, nausea, dizziness, sleep disturbances;

From the side of the cardiovascular system: often a feeling of palpitations;

On the part of the respiratory system: often candidiasis of the mucous membrane of the oral cavity and pharynx, cough, hoarseness of voice, mild irritation in the throat;

Allergic reactions: rarely immediate and delayed hypersensitivity reactions (eg, urticaria, angioedema, anaphylactic reactions).

Storage method:

In a dry, dark, cool place at a temperature not exceeding 30 degrees.

Package:

120 doses – plastic inhalers with control of the first opening (protective film indicating the place of opening) – packs of cardboard.